# Safety and Efficacy Study in Patients With Major Depressive Disorder

> **NCT00896363** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 99 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** GSK163090 1 mg
- **DRUG:** GSK163090 Placebo
- **DRUG:** GSK163090 3 mg

## Key facts

- **NCT ID:** NCT00896363
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-23
- **Primary completion:** 2010-02-09
- **Final completion:** 2010-02-09
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896363, "Safety and Efficacy Study in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00896363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*